Shaanxi Panlong Pharmaceutical Group Co., Ltd. Stock: price and insider trades · China
盘龙药业
No insider purchase over the last 90 days. The latest, by 张德柱, was filed 20 Jun 2023.
Shaanxi Panlong Pharmaceutical Group Co., Ltd.: what insiders have been doing
This page follows insider dealings at Shaanxi Panlong Pharmaceutical Group Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. Between 4 November 2025 and 4 November 2026, 1 insider published 1 filing.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €95k. At €95k, the sale published on 12 March 2026 by 朱文锋 is the largest of the period.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 521 companies we follow on the same exchange. Our records for Shaanxi Panlong Pharmaceutical Group Co., Ltd. go back to 2022, with 1 purchase and 2 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -36.3%Entry CN¥41.64 · Close at T+365 CN¥26.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Shaanxi Panlong Pharmaceutical Group Co., Ltd.
盘龙药业 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of innovative medicines.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
